TIDMOBI
Ondine Biomedical Inc.
18 October 2023
18 October 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Steriwave shown to reduce resistant bacteria by >99.9%
-- New research presented by Ondine shows that Steriwave
photodisinfection reduces antibiotic-resistant bacteria by more
than 99.9% without generating resistance.
-- The research suggests that photodisinfection is a viable alternative to antibiotics.
Canadian life sciences company Ondine Biomedical Inc. (LON: OBI)
is today presenting new research showing that Steriwave (R)
photodisinfection reduced antibiotic-resistant bacteria by more
than 99.9%. The in vitro study, which is being presented today at
the IP2023 Annual conference taking place in Liverpool 17-19
October 2023, indicates that photodisinfection is likely to play an
important role in strategies for combatting antimicrobial
resistance (AMR).
The controlled study evaluated the efficacy of Ondine's
Steriwave (R) photodisinfection against Gram-negative and
Gram-positive multidrug-resistant (MDR) and extensively
drug-resistant (XDR) bacteria with novel antibiotic resistance
factors. All of the bacterial strains used in the study exhibited
resistance against some of the most commonly prescribed antibiotic
classes, including penicillin, tetracyclines, quinolones and
carbapenems.
The results of the study showed that treatment with
photodisinfection resulted in >99.9% reduction of viable
bacteria compared to the control, regardless of the antibiotic
susceptibility of the bacteria. The authors concluded that
photodisinfection is likely an important adjunct to AMR strategies
in the future and that further clinical studies are warranted.
Antimicrobial resistance (AMR) remains a major public health
concern, causing 33,000 deaths in Europe annually ([1]) which is
projected to rise to over 10 million globally by 2050. ([2]) There
are widespread multidrug-resistant (MDR) and extensively
drug-resistant (XDR) infections across the world which are mainly
caused by Gram-negative bacteria including Enterobacteriaceae and
P. aeruginosa AMR bacteria ([3]) (, [4]) and Gram-positive bacteria
such as Staphylococcus spp. ([5]) Steriwave has been found to be
highly effective against all these pathogens.
Photodisinfection uses a photosensitizer and a specific
wavelength of light to trigger photochemical reactions that produce
reactive oxygen species. These reactive oxygen species are lethal
to a broad spectrum of microbes, including bacteria, fungi, and
viruses. Importantly, photodisinfection does not induce
antimicrobial resistance formation.
Carolyn Cross, CEO of Ondine, commented:
"We continue to demonstrate, both clinically in hospitals across
Canada and in the lab, that photodisinfection can provide a real
alternative to topical antimicrobials which are no longer effective
against an increasing number of pathogens. The evidence continues
to show that photodisinfection destroys all types of pathogens
including viruses, bacteria and fungi even those in biofilm, and we
believe this technology can save millions of lives. The results of
this study are particularly welcome as we prepare for our US Phase
3 trial in partnership with HCA Healthcare who are providing
invaluable guidance and support."
The poster presentation, "Antimicrobial Photodynamic Therapy
Against Extensively Drug-Resistant (XDR) Gram Negative Isolates
With Novel Antibiotic Resistance Factors", is being presented at
IP2023 between 1:10pm and 2:40pm (BST) on 18 October 2023. The full
poster is available to download here.
Ondine Biomedical Inc.
+001 (604) 665
Carolyn Cross, CEO 0555
Singer Capital Markets (Nominated Adviser
and Joint Broker)
+44 (0)20 7496
Aubrey Powell, Asha Chotai, Sam Butcher 3000
RBC Capital Markets (Joint Broker)
+44 (0)20 7653
Rupert Walford, Kathryn Deegan 4000
Vane Percy & Roberts (Media Contact)
+44 (0)77 1000
Simon Vane Percy, Amanda Bernard 5910
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company
innovating in the field of photodisinfection therapies. Ondine has
a pipeline of investigational products, based on its proprietary
photodisinfection platform, in various stages of development.
Products beyond nasal photodisinfection include therapies for a
variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.
About photodisinfection
Ondine's photodisinfection is a patented technology using a
proprietary photosensitizer (non-antibiotic, light-activated
solution) to destroy pathogens. When illuminated with a specific
wavelength of light, the photosensitizer is activated, causing an
oxidative burst that is lethal to all types of pathogens.
Ondine's nasal photodisinfection system has a CE mark and is
approved in Canada and several other countries under the name
Steriwave(TM). It has been used in Canada for over ten years, with
no serious adverse events reported. In the US, it is currently
undergoing clinical trials for regulatory approval.
[1] WHO Regional Office for Europe/European Centre for Disease
Prevention and Control. Antimicrobial resistance surveillance in
Europe 2022 - 2020 data. Copenhagen: WHO Regional Office for
Europe; 2022.
[2] "O'Neill Review into Antibiotic Resistance"
https://researchbriefings.files.parliament.uk/documents/CDP-2017-0074/CDP-2017-0074.pdf
[3] Cassini A, Högberg LD, Plachouras D, et al. Attributable
deaths and disability-adjusted life-years caused by infections with
antibiotic-resistant bacteria in the EU and the European Economic
Area in 2015: a population-level modelling analysis. Lancet Infect
Dis. 2019;19(1):56-66. doi:10.1016/S1473-3099(18)30605-4
[4] Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant
Gram-negative bacteria: a systematic review of current
epidemiology, prognosis and treatment options. J Antimicrob
Chemother. 2020;75(2):271-282. doi:10.1093/jac/dkz401
[5] UK Health Security Agency. MRSA, MSSA, Gram-negative
bacteraemia and CDI: 30-day all-cause fatality, London: UK Health
Security Agency, March 2023.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUBSAROBURAUA
(END) Dow Jones Newswires
October 18, 2023 02:00 ET (06:00 GMT)
Ondine Biomedical (LSE:OBI)
過去 株価チャート
から 4 2024 まで 5 2024
Ondine Biomedical (LSE:OBI)
過去 株価チャート
から 5 2023 まで 5 2024